Multiple myeloma is a haematological cancer caused by malignant plasma cells in the bone marrow that can result in organ dysfunction and death. Recent novel treatments have contributed to improved survival rates, including monoclonal antibody therapies that target the CD38 protein on the surface of plasma cells. Anti-CD38 therapies are IgG kappa monoclonal antibodies that are given in doses high enough for the drug to be visible on serum protein electrophoresis as a small paraprotein. We present a case where isatuximab, the most recent anti-CD38 monoclonal antibody to be approved for treatment of myeloma, obscured the patient’s paraprotein on gel immunofixation, so that complete remission could not be demonstrated. This was resolved using the isatuximab Hydrashift assay. The interference on gel immunofixation was unexpected because isatuximab migrated in a position distinct from the patient’s paraprotein on capillary zone electrophoresis. We demonstrate the surprising finding that isatuximab migrates in a different position on gel electrophoresis compared to capillary zone electrophoresis. It is vital that laboratories are aware of the possible interference on electrophoresis from anti-CD38 monoclonal antibody therapies, and are able to recognise these drugs on protein electrophoresis. The difference in isatuximab’s electrophoretic mobility on capillary and gel protein electrophoresis makes this particularly challenging. Laboratories should have a strategy for alternative analyses in the event that the drugs interfere with assessment of the patient’s paraprotein.

1. Cancer Research UK . website. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma#heading-Two https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma#heading-Two.accessed September 2021
Google Scholar2. Kumar, S, Paivar, B, Anderson, KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17(8): e328–e346.
Google Scholar | Crossref | Medline3. Murata, K, McCash, SI, Carroll, B, et al. Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Clin Biochem 2018; 51: 66–71.
Google Scholar | Crossref | Medline4. Sheldon, J, Wheeler, RD, Powles, R. Electrophoretic patterns post daratumumab. Ann Clin Biochem 2018; 55(2): 299–301.
Google Scholar | SAGE Journals | ISI5. Wuyts, B, Bossuyt, X, Verhoef, G, et al. Conflicting results between electrophoresis methods of serum M-proteins. Electrophoresis 2004; 25(10–11): 1548–1550.
Google Scholar | Crossref | Medline6. Keren, DR . Protein Electrophoresis in Clinical Diagnosis. 2nd ed. Chicago, IL: American Society for Clinical Pathology Press, 2012.
Google Scholar | Crossref7. Bossuyt, X . Interferences in clinical capillary zone electrophoresis of serum proteins. Electrophoresis 2004; 25(10–11): 1485–1487.
Google Scholar | Crossref | Medline8. Wheeler, RD, Zhang, L, Sheldon, J. Large abnormal peak on capillary zone electrophoresis due to contrast agent. Ann Clin Biochem 2018; 55(5): 608–611.
Google Scholar | SAGE Journals | ISI9. McCudden, CR, Voorhees, PM, Hainsworth, SA, et al. Interference of monoclonal antibody therapies with serum protein electrophoresis tests. Clin Chem 2010; 56(12): 1897–1899.
Google Scholar | Crossref | Medline10. Jacobs, JFM, Turner, KA, Graziani, MS, et al. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins. Clin Chem Lab Med 2020; 58(4): 547–559.
Google Scholar | Crossref | Medline